Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The company has the backing of a huge fund manager that will put up $3b to start the development. I hear that he was in charge of the Templeton fund. The local government has approved the project and it now is in the hands of the Ministry. Tet holiday is about over and then news should be out.
"Meantime I'm buying GCHC. There is NO comparison as to which is going higher or has more on the table. If this casino deal goes through as expected-GCHC is valued @$25.00 PPS and with the OS being less than 25mm with NO debt-$30+ is a better estimate"
Sounds very lucrative.
Interesring, placed that one on my screen. Took a nice profit yesterday on CNSJ, did'nt think it was going to stay up there!
Happy Chinese New Year to everyone!!!
I'm watching. Meantime I'm buying GCHC. There is NO comparison as to which is going higher or has more on the table. If this casino deal goes through as expected-GCHC is valued @$25.00 PPS and with the OS being less than 25mm with NO debt-$30+ is a better estimate.
Rumor is that CNSJ has financial audits well into the tens of millions of dollars.
Well north of here if the audits come out soon while the iron is hot.
The Chinese certainly use alot of coal! :)
GCHC-the rumor has it-multi billion dollar deal is about to be inked. This pup is going north as soon as the news is released. ;)
China Shuangji Cement Ltd. Announces Corporate Update
Tuesday February 5, 8:30 am ET
ZHAOYUAN CITY, SHANDONG, CHINA--(MARKET WIRE)--Feb 5, 2008 -- China Shuangji Cement Ltd. (OTC BB:CNSJ.OB - News) ("China Shuangji" or "the Company") today announces a corporate update and an action plan for this quarter.
ADVERTISEMENT
"The change to our corporate name and ticker symbol on November 9, 2007 marks a new direction for the Company," said China Shuangji Chairman and President Wenji Song.
China Shuangji expects to receive the audited financial statements of Shandong Zhaoyuan Shuangji Group Co., Ltd. ("SZSG") and contemplates filing the necessary Form 8-K with the Securities and Exchange Commission on a series of contractual agreements with SZSG, a domestic company registered in the People's Republic of China which is engaged in the business of manufacturing of cement products.
Mr. Song further stated, "I believe that each company has undeveloped endless potential. Looking ahead, our Company faces valuable developmental opportunities, along with many difficulties and challenges. We will execute the development strategies already approved, on the basis of the strengthening cement industry, to implement brand name effectiveness, and to expand in both the domestic and international markets. Our focus will be on leveraging the Company's strengths and stepping up business development, in order to provide the best products to our customers and as well to make Shuangji a large-scale international corporation. The Company is in the new historic development stage. We will continue to do what is necessary to establish strong corporate governance, in order to protect the interests of the Company and all shareholders. With the support of all our shareholders, and the combined efforts of the Board of Directors, management and staff, I firmly believe that Shuangji is blessed with a very promising future."
Forward-looking Statements
The information contained herein includes forward-looking statements. These statements relate to future events or to our future anticipated financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We do not intend to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
Contact:
For more information, please contact:
Investor Relations Contact:
Tel: 1-866-365-4724
http://www.shuangjicement.com
--------------------------------------------------------------------------------
Source: China Shuangji Cement Ltd.
One that may be of interest, and it's fully reporting OTCBB, and that is CNSJ, here is news from them.
China Shuangji Cement Ltd. Announces Corporate Update
2008-02-05 08:30 ET - News Release
ZHAOYUAN CITY, SHANDONG, CHINA -- (MARKET WIRE) -- 02/05/08
China Shuangji Cement Ltd. (OTCBB: CNSJ) ("China Shuangji" or "the Company") today announces a corporate update and an action plan for this quarter.
"The change to our corporate name and ticker symbol on November 9, 2007 marks a new direction for the Company," said China Shuangji Chairman and President Wenji Song.
China Shuangji expects to receive the audited financial statements of Shandong Zhaoyuan Shuangji Group Co., Ltd. ("SZSG") and contemplates filing the necessary Form 8-K with the Securities and Exchange Commission on a series of contractual agreements with SZSG, a domestic company registered in the People's Republic of China which is engaged in the business of manufacturing of cement products.
Mr. Song further stated, "I believe that each company has undeveloped endless potential. Looking ahead, our Company faces valuable developmental opportunities, along with many difficulties and challenges. We will execute the development strategies already approved, on the basis of the strengthening cement industry, to implement brand name effectiveness, and to expand in both the domestic and international markets. Our focus will be on leveraging the Company's strengths and stepping up business development, in order to provide the best products to our customers and as well to make Shuangji a large-scale international corporation. The Company is in the new historic development stage. We will continue to do what is necessary to establish strong corporate governance, in order to protect the interests of the Company and all shareholders. With the support of all our shareholders, and the combined efforts of the Board of Directors, management and staff, I firmly believe that Shuangji is blessed with a very promising future."
Forward-looking Statements
The information contained herein includes forward-looking statements. These statements relate to future events or to our future anticipated financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We do not intend to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
For more information, please contact:
Investor Relations Contact:
Tel: 1-866-365-4724
www.shuangjicement.com
not holding the bag on this one waiting played the dips nicely. expecting to see more news regarding Germany very soon.
Intermost Receives 2007 Dividends from Invested Shenzhen Exchange
Sunday February 3, 10:00 am ET
SHENZHEN, China, Feb. 3 /Xinhua-PRNewswire/ -- The Intermost Corporation (OTC Bulletin Board: IMOT - News), a leading electronic online equity exchange service provider in China, announced the receipt of approximately 2,000,000 RMB (approximately USD$280,000) in dividends from the Shenzhen International Hi-Tech Property Right Exchange Center (Shenzhen Exchange), following on from the 830,000 RMB (approximately USD$115,000) received in 2006, in which the IMOT Information Technology (Shenzhen) Co., Ltd., the wholly-owned subsidiary of Intermost Corporation, has a 15% shareholding position.
ADVERTISEMENT
Facing the rapid growth of the Shenzhen Exchange, the CFO of the Intermost Corporation, Mr. Thomas Lee, is pleased to comment, "It has been proved that the deal with the Shenzhen Exchange is good deal and it will substantially increase the equity interest of the Intermost Corporation. As an important shareholder and close partner, Intermost Corporation will fully collaborate with the Shenzhen Exchange. The management of Intermost Corporation will try their best to increase the revenue and profit in the coming period of time through these deals."
In December 12, 2006, the IMOT Information Technology (Shenzhen) Co., Ltd. expended approximately USD$800,000 to replace the formerly issued 2,470,355 shares of the Intermost Corporation stock to gain a 15% shareholding position in the Shenzhen Exchange. The Shenzhen Exchange has demonstrated excellent performance in 2007 and it ranks as the best performing equity exchange institution in South China. With its business spreading throughout nine provinces in South China, it is among the few profitable equity institutions in China.
About the Intermost Corporation
Founded in the USA in September 1998, the Intermost Corporation was the first Chinese Internet company listed on the US OTC Bulletin Board (stock symbol: IMOT) in December 1998. The Intermost Corporation has focused its services on the booming Equity Exchange Market in China, including equity- related solution development, equity quotes and information provision, electronic online equity exchange services, direct investment in regional equity exchanges, business incubation services for well-performing innovative enterprises, investment consulting services for overseas listings, the equity portal website -- China Equity Exchange Platform ( http://www.chinae.com ), and other services.
CBPC .008 X 0.009 chinabiopharma
Holding waiting for news
Home page
http://chinabiopharma.net/index_1_1.asp
Thanks T. Might add SNEN to that group too.
Hope you are having a great vacation!
PUDC $0.70 very nice finish:
TTCH .007 X .008 ..besides recently announcing a $13.2 Million contract..this water related company is now is embarking on a strategic acquisition program related to the Company's water supply business. They expect the growing demand for clean water delivery, flood control systems and water related business in China to continue to drive demand for their products in 2008 and beyond. READ THE RECENT NEWS:
TTCM China Announces Strategic Acquisition of IC-Based Smart Card Water-Meter Business
TIANJIN, China--(BUSINESS WIRE)--
TTCM China, Inc. (Pink Sheets:TTCH), a leading producer and supplier of glass-reinforced fiber plastic pipes, today announced the acquisition of ShiJiaZhuang HuaTeng Technology Company who is engaged in the design and manufacturing of IC-based smart card water-meters as a strategic acquisition related to the water supply industry.
The Company is expected to complete the audit and evaluation of the IC-based smart card water-meter company within this month. The acquired company has the annual production capacity of 300,000 units of such high-technology water-meters.
Mr. Jiqun Wang, Founder and Chairman of TTCM China, said, "TTCM is embarking on the strategic acquisition program and this is the first of such acquisition related to the Company's water supply business. We expect the growing demand for clean water delivery, flood control systems and water related business in China to continue to drive demand for our products in 2008 and beyond".
About TTCM China, Inc.
TTCM China, founded in 1995 and based in Tianjin China, is a leading producer of glass-reinforced composite plastic products including regular and high-pressure pipes, fittings related to the water supply and sewerage systems. In cooperation with the Harbin Industry University, TTCM developed an advanced technology employing micro-emulsification, which enables a reduction of the amount of resin used in the production process and at the same time raises the product compactness, strength and infiltration quality. These procedures make TTCM's glass-reinforced plastic pipes superior in strength to plastic pipes while they only weigh one-fourth the weight of regular steel pipes.
The company is in negotiations with a several provincial and municipal government agencies and private companies concerning the requirements of pipes for water supply systems, sewerage systems and flood control systems.
For more information, visit http://www.ttcmchina.com.
unbelievable. eom
GCHC has been granted approval to incorporate in Bermuda and news will be released very soon. The 2yrs of audits are being sent, the directors will meet in Bermuda as required and all GCHC shares will be exchanged on a 1 for 1 basis. Stay tuned for the fireworks. NO DEBT-min float ~25mm shares, 5 deals active each worth over 100mm and foreign investors will get tax advantages which encourages them to buy. Happy New Year!!
Favorite Chinese picks: SUOT LTUS YHGG all with extremely low PE ratios and one that may do well possibly is CECU a .06 stock that is working on merging with a Chinese company PanPacific...called IR and they said news could come out within the next couple of weeks. CHNG an old favorite really popped today but not in now...CNOA ran up nicely from a buck to 1.50's the past 3 days but out now and may rebuy CNEH again as I'd done well in it too in the past. A very nice board you've got here...congrats! Heading out for supper and then heading out for vacation early in the morning so catch you in a couple of weeks! All the best!! tuna
I believe PUDC shall rise a lot of more maybe back to 0.80 after passing 0.55. There is a gap to fill between 0.70 and 0.60 if you look at the chart.
GS any thoughts on PUDC? TIA
I am starting to get some CJGH. If the market rallies and bounce, no reasons this stock won't go over $1 again.
SEED 8.31 x 8.38 last 8.39 and rising!!!
What are you into that looks interesting?
CJGH made a round trip from China to US, and now back to China, hope the next trip goes well to Germany. I wish none of you bagholded it over $5, dangerous game.
PUDC - 0.40s, bought some, shall go up from this level, looking for two/three more days with green finish IMHO.
Yes I'm around. LOL
Hope you are doing well. GLTU
MGH .79 looks to have some nice upside to it!
.042 any updates?
You still around?
CJGH participating in CHinese government Five-Year Technology Development Program of Steel Ball Industry. news is out
Press Release Source: China Jiangsu Golden Horse
China Jiangsu Golden Horse Steel Ball Participates in Chinese Government's Five-Year Technology Development Program of Steel Ball Industry
Tuesday January 22, 8:30 am ET
XUYI, JIANGSU, CHINA--(MARKET WIRE)--Jan 22, 2008 -- China Jiangsu Golden Horse Steel Ball, Inc. (Other OTC:CJGH.PK - News) ("Golden Horse" or "the Company") a leading Chinese manufacturer and supplier of ball bearings, wishes to announce that its controlled affiliate, Jiangsu Golden Horse Steel Ball Co., Ltd. ("Jiangsu Golden Horse") will take an active role in the Chinese Government's 11th five-year technology development plan of the steel ball industry, which is formulated based on the requirements of China's Bearing Industry 11th five-year development program, has been approved by China Bearing Industry Association Technology Committee.
ADVERTISEMENT
Jiangsu Golden Horse, a domestic People's Republic of China company, will undertake several new technology developments in the steel ball industry for 2008 and 2009. Three programs are slated for 2008 and will include the research of G3 grade high-precision steel balls, the research of new resin grinding wheel milling techniques, and the development of automotive bearing steel wire. In 2009, three programs will research the life span test machine of steel balls, development of steel ball line processing technology, and the development of cold heading active control technology of steel balls.
"We take great pride to take an active role in the government's 11th Five-Year Technology Development Program of Steel Ball Industry in China and continue our leading position in the steel ball industry," stated Qiang Ma, President of China Jiangsu Golden Horse Steel Ball, Inc. "Our company employs more than 50 engineers and we look forward to the research and development programs to improve the equipment, the product quality and technologies of steel ball production."
About Us:
The Company along with its affiliates and controlled entities is one of the top five manufacturers of steel ball bearings in China. The Company produces over three billion ball bearings annually of various specifications along with its development of over 15 new products, such as stainless steel balls, aluminium balls, and ceramics balls. In addition, the Company continues to export its products to over twenty countries worldwide including the USA, Japan, Brazil, India, and Germany.
Forward-looking Statements:
The information contained herein includes forward-looking statements. These statements relate to future events or to our future anticipated financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We do not intend to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
Contact:
Contact:
Investor Relations Contact:
Tel: 1-866-365-4724
Website: http://www.goldenhorsesteel.com
--------------------------------------------------------------------------------
Chinese Tech stock: (FDVE) $1.30
A/S 150,000,000 (10,000,000 Preferred)
O/S 1,857,000 (1,651,500 Restricted)
Float: 205,500 as of 8/10/07
Estimated Free-float Market Cap: 267,150 as of Right Now!
http://investorshub.advfn.com/boards/board.asp?board_id=10009
You are very sharp. Looks like you have done the DD out of the WAZOOO on this one.
Take a look at this chinese play:(CCPM)
http://investorshub.advfn.com/boards/board.asp?board_id=11527
CBPC - Takeda - is the Rozerem company
Abe Lincoln Commercial
Rozerem™ ramelteon MT1/MT2 receptor agonist for Insomnia
http://www.takeda.com/
Looking for company to update shareholders on
this 8K Filing info
CHINA BIOPHARMA, INC. 8-K 11/20/2007 11/19/2007
http://www.nasdaq.com/asp/quotes_sec.asp?selected=CBPC
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 19, 2007
China Biopharma, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
000-50005 04-3703334
(Commission File Number) (IRS Employer Identification No.)
31 Airpark Road
Princeton, New Jersey 08540
--------------------------------------------------------------------------------
(Address of principal executive offices and zip code)
609-651-8588
--------------------------------------------------------------------------------
(Registrant’s telephone number including area code)
_____________________________________________________
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Item 8.01 - Other Events
Plan of Operation
China Biopharma has most of its operation in China and was involved mainly in human vaccine business. The vaccine business has become more competitive and recent SFDA (State Food and Drug Administration) turmoil has created uncertainties in this highly regulated sector. In order to improve the company’s operating performance and cope with the changing environment, Management has adjusted the strategy and formulated a new business plan. Starting from this year we have started to distribute some specialty drug products. The company plans to take more control on the available cash in our subsidiaries and move into higher market potential and higher margin specialty pharmaceutical products.
Take Closer Control on Subsidiaries
China Biopharma is working to take direct control on subsidiaries’ operation and financial management instead of relying on the joint venture partner’s performance. We plan to increase our shareholding in our current joint venture in China, Zhejiang Tianyuan Biotech Co., Ltd., and eventually to have 100% control and ownership in this joint venture (afterwards we plan to change its name to Zhejiang Baicon Pharmaceutical Co., Ltd.), with internally available resources. There would be no need to raise additional capital to complete the transactions. Recently we have reached agreement with our joint venture partner to increase our control on the joint venture operation and its subsidiary, Hainan CITIC. We expect this will improve our current performance and increase operation stability. We also expect this will help to preserve available cash position and give us more operation flexibility.
Move Away from Low Margin Vaccine Business
China Biopharma plans to move away from low margin vaccine business and focus on higher margin vaccine and specialty drug. Due to the recent changes in vaccine sectors, more and more vaccine manufacturers have entered low margin vaccine business such as flu vaccine, which created severe competition among, and squeezed profit margin of, vaccine distributors. To avoid these direct competitions, the company is negotiating with a few global vaccine manufacturers for carrying their higher margin products.
Enter Specialty Pharmaceutical Products
The company has worked with the Japanese pharmaceutical company, Takeda Pharmaceutical Company, Ltd. (“Takeda”), the largest pharmaceutical company in Japan. With global headquarters located in Osaka, Japan, Takeda specializes in the research and development of breakthrough drugs, and has marketing operations throughout U.S., Europe, and Asia. In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drugs market, in which it holds the second largest domestic share.
After distributing its products for about ten months on a trial basis, both parties are quite happy with the outcomes and decide to continue this relationship and we will commit more resources and increase our capabilities to carry Takeda’s products.
Release Antiviral Products
China Biopharma has worked with Soonfast Pharmaceutical Science & Technology Co., Ltd. (“Soonfast”) to introduce a new antiviral medicine into the overseas market including the United States and European countries. This all-natural product has been approved in China for external use to treat human papillomavirus (“HPV”) and herpes simplex virus (“HSV”). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV by 90% within only 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33.
--------------------------------------------------------------------------------
Human papillomavirus infection is common across all races and socioeconomic groups and is prevalent throughout the world in sexually active persons. HPVs are the most common sexually transmitted viral agents in the United States, infecting up to 20% people aged 15 to 49. In the last 30 years, the incidence of HPV infection has increased dramatically. Despite the prevalence of HPV, no available drug therapy effectively eliminates HPV infection and replication or prevents HPV-associated malignant progression. Consequently, there is an urgent medical need unmet for the development of safe and effective therapies for HPV-associated diseases. According to a research by Decision Resources, the market for HPV treatment is expected to grow from $135 million in 2002 to $1.4 billion (€1.08 billion) in 2012.
The commercial product has been released this month, and China Biopharma will distribute this product in certain regions in China and has right to distribute it in all overseas markets, including the United States. China Biopharma will work with existing distribution channels in China and in United States to sell these products. We expect to have distribution margin over 30% and 35% in China and in the United States, respectively.
Improve Current Operation Results
After almost a year to establish our footing into China, the company has adjusted itself to fit into this complicated market environment and business landscape. In view of improvement and progress on our current operation results, the company plans to take above steps to strengthen its control over operating subsidiaries, preserve cash, apply available resources to, and refocus on, higher margin, less competitive products with greater market potential.
Safe Harbor Statement
Some of the statements made in this document discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHINA BIOPHARMA, INC.
By: /s/ Peter Wang
Name: Peter Wang
Title: CEO and Chairman of the Board
Date: November 19, 2007
Who is "Takeda"
The company has worked with the Japanese pharmaceutical company, Takeda Pharmaceutical Company, Ltd. (“Takeda”), the largest pharmaceutical company in Japan. With global headquarters located in Osaka, Japan, Takeda specializes in the research and development of breakthrough drugs, and has marketing operations throughout U.S., Europe, and Asia. In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drugs market, in which it holds the second largest domestic share.
After distributing its products for about ten months on a trial basis, both parties are quite happy with the outcomes and decide to continue this relationship and we will commit more resources and increase our capabilities to carry Takeda’s products.
Thanks - CBPC
Been in this stock a few months
2008 - Outlook - depends on the below update shareholders
are waiting on -
Looking for company to update shareholders on
this 8K Filing info
CHINA BIOPHARMA, INC. 8-K 11/20/2007 11/19/2007
http://www.nasdaq.com/asp/quotes_sec.asp?selected=CBPC
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 19, 2007
China Biopharma, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
000-50005 04-3703334
(Commission File Number) (IRS Employer Identification No.)
31 Airpark Road
Princeton, New Jersey 08540
--------------------------------------------------------------------------------
(Address of principal executive offices and zip code)
609-651-8588
--------------------------------------------------------------------------------
(Registrant’s telephone number including area code)
_____________________________________________________
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Item 8.01 - Other Events
Plan of Operation
China Biopharma has most of its operation in China and was involved mainly in human vaccine business. The vaccine business has become more competitive and recent SFDA (State Food and Drug Administration) turmoil has created uncertainties in this highly regulated sector. In order to improve the company’s operating performance and cope with the changing environment, Management has adjusted the strategy and formulated a new business plan. Starting from this year we have started to distribute some specialty drug products. The company plans to take more control on the available cash in our subsidiaries and move into higher market potential and higher margin specialty pharmaceutical products.
Take Closer Control on Subsidiaries
China Biopharma is working to take direct control on subsidiaries’ operation and financial management instead of relying on the joint venture partner’s performance. We plan to increase our shareholding in our current joint venture in China, Zhejiang Tianyuan Biotech Co., Ltd., and eventually to have 100% control and ownership in this joint venture (afterwards we plan to change its name to Zhejiang Baicon Pharmaceutical Co., Ltd.), with internally available resources. There would be no need to raise additional capital to complete the transactions. Recently we have reached agreement with our joint venture partner to increase our control on the joint venture operation and its subsidiary, Hainan CITIC. We expect this will improve our current performance and increase operation stability. We also expect this will help to preserve available cash position and give us more operation flexibility.
Move Away from Low Margin Vaccine Business
China Biopharma plans to move away from low margin vaccine business and focus on higher margin vaccine and specialty drug. Due to the recent changes in vaccine sectors, more and more vaccine manufacturers have entered low margin vaccine business such as flu vaccine, which created severe competition among, and squeezed profit margin of, vaccine distributors. To avoid these direct competitions, the company is negotiating with a few global vaccine manufacturers for carrying their higher margin products.
Enter Specialty Pharmaceutical Products
The company has worked with the Japanese pharmaceutical company, Takeda Pharmaceutical Company, Ltd. (“Takeda”), the largest pharmaceutical company in Japan. With global headquarters located in Osaka, Japan, Takeda specializes in the research and development of breakthrough drugs, and has marketing operations throughout U.S., Europe, and Asia. In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drugs market, in which it holds the second largest domestic share.
After distributing its products for about ten months on a trial basis, both parties are quite happy with the outcomes and decide to continue this relationship and we will commit more resources and increase our capabilities to carry Takeda’s products.
Release Antiviral Products
China Biopharma has worked with Soonfast Pharmaceutical Science & Technology Co., Ltd. (“Soonfast”) to introduce a new antiviral medicine into the overseas market including the United States and European countries. This all-natural product has been approved in China for external use to treat human papillomavirus (“HPV”) and herpes simplex virus (“HSV”). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV by 90% within only 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33.
--------------------------------------------------------------------------------
Human papillomavirus infection is common across all races and socioeconomic groups and is prevalent throughout the world in sexually active persons. HPVs are the most common sexually transmitted viral agents in the United States, infecting up to 20% people aged 15 to 49. In the last 30 years, the incidence of HPV infection has increased dramatically. Despite the prevalence of HPV, no available drug therapy effectively eliminates HPV infection and replication or prevents HPV-associated malignant progression. Consequently, there is an urgent medical need unmet for the development of safe and effective therapies for HPV-associated diseases. According to a research by Decision Resources, the market for HPV treatment is expected to grow from $135 million in 2002 to $1.4 billion (€1.08 billion) in 2012.
The commercial product has been released this month, and China Biopharma will distribute this product in certain regions in China and has right to distribute it in all overseas markets, including the United States. China Biopharma will work with existing distribution channels in China and in United States to sell these products. We expect to have distribution margin over 30% and 35% in China and in the United States, respectively.
Improve Current Operation Results
After almost a year to establish our footing into China, the company has adjusted itself to fit into this complicated market environment and business landscape. In view of improvement and progress on our current operation results, the company plans to take above steps to strengthen its control over operating subsidiaries, preserve cash, apply available resources to, and refocus on, higher margin, less competitive products with greater market potential.
Safe Harbor Statement
Some of the statements made in this document discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHINA BIOPHARMA, INC.
By: /s/ Peter Wang
Name: Peter Wang
Title: CEO and Chairman of the Board
Date: November 19, 2007
CKGT looks very impessive and seems to have a big following behind it.
You are making me very curios on CKGT now.
Go_Stocks you are now the second person to mention that stock ticker to me.
First question would be: How many shares are outstanding and what is the public float?
Very nice chart and thank you. I will try to do some DD on it over the weekend.
Question: How long are you on this company and what is their 2008 outlook.
CLCL China/beverage play/Beijing 2008
Olympics
http://investorshub.advfn.com/boards/board.asp?board_id=11143
I have been digging for more material. If anyone has info that I could add to the iBox I'd appreciate it much.. ;)
Calcol, which has shares trading under the symbol 'CLCL' on the OTC Bulletin Board in the US, succeeded at securing one of three business licenses for manufacturing of foreign-branded soft drinks in China and says it is rapidly capturing market share from the other two major higher-priced American brands {Coke and Pepsi} .
Its recent expansion into 160 large retail stores in China, including nationwide sales and distribution agreements with Tesco, Carrefour, Wal-Mart, Lotus, Trust-Mart, Bonjour, and Ren Ren Le, marks the start of a major business development cycle with China-based revenues expected to grow to 16.9 million USD and operating profits projected at 2 million USD by 2008.
Website: http://calcol.com/ http://malibu-cola.com/
MALIBU-COLA is produced in China under exclusive license from CALCOL INC. which owns and operates a modern 110,000 square foot state-of-the-art 13 million standard case bottling and canning plant and 800,000 unit concentrate plant on 10 acres of Beijing.
MALIBU-COLA to Introduce DRAGON-ADE ENERGY for the 2008 Beijing
Olympics, and Vitamin-Enriched Flavored Waters; Expanding Sales, Exploring
Strategic Options
BEIJING & CLEVELAND, Jun 08, 2007 (BUSINESS WIRE) -- CALCOL INC. (CLCL-OTC)
MALIBU-COLA BEVERAGE CO. LTD. China subsidiary announced today planned
introduction of DRAGON-ADE ENERGY(China TM pending) for the Beijing 2008
Olympics. http://markets.chron.com/chron?GUID=2278958&Page=MediaViewer&Ticker=CLCL
Both are at record highs, and MGH does both. Lots of potential here.
Gold and Silver in CHINA is big out there is it not?
HOGS on radar, thanks for your DD!
HOGS - one of the new Chinese stocks moved to NASDAQ global recently at 52 weeks high.
HOGS chart:
Zhongpin Approved to List on the Nasdaq Global Select Market
CHANGGE CITY, China, Dec. 26 /Xinhua-PRNewswire-FirstCall/ -- Zhongpin Inc. (OTC Bulletin Board: ZHNP) ('Zhongpin'), a leading meat and food processing company in the People's Republic of China ('PRC'), announced that it has received approval for listing on the Nasdaq Global Select Market.
Zhongpin plans to start trading on the Nasdaq Global Select Market from December 27, 2007. Nasdaq has reserved HOGS as the trading symbol for Zhongpin's common stock.
'We are extremely pleased to be approved to list our common stock on the Nasdaq Global Select Market,' commented Mr. Xianfu Zhu, Chairman and CEO of Zhongpin. 'Having our common stock listed on the Nasdaq Global Select Market is an important part of our goal to increase our profile in the international markets as we help advance the modernization of China's meat processing industry. We believe that our listing on the Nasdaq will increase our visibility and liquidity as well as expand our pool of investors.'
About Zhongpin
Zhongpin is a meat and food processing company that specializes in pork and pork products, and fruits and vegetables, in the PRC. Its distribution network in the PRC spans more than 20 provinces and includes over 2,800 retail outlets. Zhongpin's export markets include the European Union, Eastern Europe, Russia, Hong Kong, Japan and South Korea. For more information, contact CCG Elite directly or visit Zhongpin's website at http://www.zpfood.com .
CBPC Chart .007 .0079
CBPC Chart
http://stockcharts.com/h-sc/ui?s=cbpc
CBPC Waiting on 1.
http://biz.yahoo.com/e/071120/cbpc.ob8-k.html
CHINA BIOPHARMA, INC. 8-K 11/20/2007 11/19/2007
http://www.nasdaq.com/asp/quotes_sec.asp?selected=CBPC
Take Closer Control on Subsidiaries
China Biopharma is working to take direct control on subsidiaries’ operation and financial management instead of relying on the joint venture partner’s performance. We plan to increase our shareholding in our current joint venture in China, Zhejiang Tianyuan Biotech Co., Ltd., and eventually to have 100% control and ownership in this joint venture (afterwards we plan to change its name to Zhejiang Baicon Pharmaceutical Co., Ltd.), with internally available resources. There would be no need to raise additional capital to complete the transactions. Recently we have reached agreement with our joint venture partner to increase our control on the joint venture operation and its subsidiary, Hainan CITIC. We expect this will improve our current performance and increase operation stability. We also expect this will help to preserve available cash position and give us more operation flexibility.
CBPC Waiting on 2
http://biz.yahoo.com/e/071120/cbpc.ob8-k.html
CHINA BIOPHARMA, INC. 8-K 11/20/2007 11/19/2007
http://www.nasdaq.com/asp/quotes_sec.asp?selected=CBPC
Move Away from Low Margin Vaccine Business
China Biopharma plans to move away from low margin vaccine business and focus on higher margin vaccine and specialty drug. Due to the recent changes in vaccine sectors, more and more vaccine manufacturers have entered low margin vaccine business such as flu vaccine, which created severe competition among, and squeezed profit margin of, vaccine distributors. To avoid these direct competitions, the company is negotiating with a few global vaccine manufacturers for carrying their higher margin products.
CBPC Waiting on 3
http://biz.yahoo.com/e/071120/cbpc.ob8-k.html
CHINA BIOPHARMA, INC. 8-K 11/20/2007 11/19/2007
http://www.nasdaq.com/asp/quotes_sec.asp?selected=CBPC
Enter Specialty Pharmaceutical Products
The company has worked with the Japanese pharmaceutical company, Takeda Pharmaceutical Company, Ltd. (“Takeda”), the largest pharmaceutical company in Japan. With global headquarters located in Osaka, Japan, Takeda specializes in the research and development of breakthrough drugs, and has marketing operations throughout U.S., Europe, and Asia. In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drugs market, in which it holds the second largest domestic share.
After distributing its products for about ten months on a trial basis, both parties are quite happy with the outcomes and decide to continue this relationship and we will commit more resources and increase our capabilities to carry Takeda’s products.
Interesting statistics, thin OS and float.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |